[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?
Authors:
- Elena TabacchiETElena Tabacchi
- Emilia FortunatiEFEmilia Fortunati
- Giulia ArgaliaGiulia Argalia
- Lucia ZanoniLZLucia Zanoni
- Diletta CalabròDCDiletta Calabrò
- Silvi TeloSTSilvi Telo
- Davide CampanaDCDavide Campana
- Giuseppe LambertiGLGiuseppe Lamberti
- Claudio RicciCRClaudio Ricci
- Riccardo CasadeiRCRiccardo Casadei
- Stefano FantiStefano Fanti
- Valentina AmbrosiniValentina Ambrosini
Open Access
Abstract
Purpose: [68Ga]Ga-DOTA-peptide uptake in the pancreatic head/uncinate process (UP) is a frequent PET/CT finding. Although mostly physiologic, it can represent a pitfall in PET/CT reading, especially when focal. An increased frequency of UP uptake has been reported in patients (pts) affected by diabetes mellitus (DM). The aim of the study is to describe the frequency of [68Ga]Ga-DOTANOC UP uptake to evaluate its variations over time and its possible correlation with DM. Methods: In September 2017, a monocentric prospective observational electronic archive was initiated at our center to collect clinical and imaging data of pts undergoing [68Ga]Ga-DOTANOC PET/CT. Among the pts enrolled in the first 6 months (Sept 2017 to Feb 2018), those presenting [68Ga]Ga-DOTANOC PET/CT uptake at UP level were included. Pts with UP lesions already documented on CT/MRI or those that underwent surgical excision of UP before PET/CT were excluded from the analysis. [68Ga]Ga-DOTANOC UP uptake was classified as diffuse or focal and compared with the pattern observed in previous PET/CT scans performed at our center. An increased frequency of UP uptake was also correlated with the presence of DM. Results: In the first 6 months, 253 pts were enrolled in the archive and 172 out of them were included in the analysis. UP increased uptake was frequently observed (77/172, 44.8%) and was mostly diffuse (62/77). In 75/172 pts (43.6%), previous [68Ga]Ga-DOTANOC PET/CT scans were available (overall 268 scans; number of previous PET per pt range: 1–20) and were retrospectively reviewed. Despite the fact that, in most pts, the uptake pattern was stable over time (54/75 pts, 72%), it changed in approximately one third of cases (21/75, 28%). Among DM pts (29/172), only 10/29 (34.4%) presented increased UP uptake. Conclusions: UP [68Ga]Ga-DOTANOC uptake is a frequent non-malignant finding (slightly higher than previously reported), mostly presenting with a diffuse pattern. However, contrary to previous reports, our data show that the pattern of uptake may vary over time in approximately one third of the cases and it is not more frequently observed in pts with DM.Keywords
This publication has 29 references indexed in Scilit:
- Quantitative Analysis of Pancreatic Polypeptide Cell Distribution in the Human PancreasPLOS ONE, 2013
- Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTA-TATE PET/CTClinical Nuclear Medicine, 2012
- Normal Uptake of 68Ga-DOTA-TOC by the Pancreas Uncinate Process Mimicking Malignancy at Somatostatin Receptor PETClinical Nuclear Medicine, 2012
- Ga-68 DOTA-NOC Uptake in the PancreasClinical Nuclear Medicine, 2012
- Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CTJournal of Nuclear Medicine, 2011
- Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticalsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- OctreoScan Positive Crohn's Disease Mimicking An Ileal Carcinoid TumorJournal of Clinical Gastroenterology, 2008
- Indium-111 Pentetreotide Uptake By Pancreatic Polypeptide Cell HyperplasiaPancreas, 2007
- Processing of Generator-Produced 68Ga for Medical ApplicationJournal of Nuclear Medicine, 2007
- Distribution of somatostatin receptors in normal and tumor tissueMetabolism, 1990